QLT receives two fast track designations for degenerative eye disease drug
QLT (TSE:QLT) (NASDAQ:QLTI) announced Wednesday it received two fast track designations from the U.S. FDA
proactive
Bacterin Receives $15 Million Credit Facility
Bacterin International Holdings (AMEX:BONE) announced Tuesday it secured a 42 month-long, $15 million credit facility with MidCap Financial LLC and Silicon Valley Bank.
IntelliCell BioSciences To Open Adipose Tissue Processing Center in Houston
IntelliCell BioSciences, Inc. (OTCQB: SVFC), maker of stromal vascular fraction that contains adipose derived adult stem cells opens new processing center in Houston, Texas.
Inovio yields long-term immune responses from cervical cancer vaccine
Inovio Pharmaceuticals reported Friday the positive long-term effects of its VGX-3100 vaccine, designed to treat cervical dysplasia and cancer caused by the human papillomavirus, or HPV.
Inherent value to be “developed and extracted” at Amphion
Amphion Innovations (LON:AMP) said it believes there is “significant inherent value to be developed and extracted” from its partner companies, when it released its annual […]
ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
NeoStem To Drive Shareholder Value, Says Rodman & Renshaw
NeoStem said Thursday that equity research firm Rodman & Renshaw re-iterated the multi-faceted stem cell company’s market outperform rating, based on “multiple milestones to drive shareholder value”.
Renovo Actively Progressing With Plans To Maximize Returns After Juvista Failure
Renovo Group (LON:RNVO) confirmed today it will be left with £33 million if it presses ahead with plans to reduce its headcount by 100.